<DOC>
	<DOC>NCT01857622</DOC>
	<brief_summary>To assess the safety and pharmacokinetics of DU-176b administered to non-valvular atrial fibrillation patients with severe renal impairment, compared with DU-176b administered to non-valvular atrial fibrillation (NVAF) patients with normal renal function or mild renal impairment (Normal/MiRI).</brief_summary>
	<brief_title>Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Patients with NVAF and SRI, or patients with NVAF and Normal/MiRI. Patients who are on hemodialysis or patients who may start hemodialysis before the followup assessment Patients who are at a significantly high risk for bleeding Patients who are receiving treatment with any anticoagulant drugs excluding warfarin, rivaroxaban, and dabigatran Patients who have evidence of hepatic function test abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>DU-176b</keyword>
	<keyword>edoxaban</keyword>
	<keyword>factor Xa</keyword>
	<keyword>oral</keyword>
	<keyword>atrial fibrillation</keyword>
	<keyword>severe renal impairment</keyword>
</DOC>